NCT05400876 - To Evaluate the Safety and Efficacy of TQB2618 Injection Combined With Penpulimab in the Treatment of Patients With Relapsed and Refractory Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 9, 2022

Primary Completion Date

May 31, 2023

Study Completion Date

October 31, 2023

Conditions

Relapsed/Refractory Lymphoma

Interventions

DRUG

TQB2618 injection

TQB2618 injection is an inhibitor of T cell immunoglobulin and mucin domain-containing protein 3 (TIM3)

DRUG

Penpulimab injection

Penpulimab is an inhibitor of programmed cell death protein 1 (PD-1)

Trial Locations (1)

RECRUITING

Sichuan Cancer Hospital, Chengdu